Kazia Therapeutics Ltd - ADR
Graf
Viktig: Aksjeinvesteringer kan over tid gi positiv avkastning, men innebærer risiko. Du kan tape deler av eller hele investeringen. Historisk avkastning for denne aksjen er ikke en pålitelig indikator på fremtidig avkastning. Data fra eksterne leverandører gjengis uendret av Saxo. Se fullstendig ansvarsfraskrivelse for data.
Om Kazia Therapeutics Ltd - ADR
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.